Page 3 - Mayo Collaborative Services News Today

Beckers asked C-suite executives from hospitals and health systems across the U. S. to share their organizations areas of growth for the next few years.  

The Supreme Court has handed down momentous decisions over the past two decades on a variety of hot-button issues. But some of the most consequential rulings — for our physical

When the world experienced a hard season of flu and respiratory illness in 2021 and 2022, European firms launched convenient, three-in-one tests for the flu, COVID, and RSV. Americans were left wondering why they weren't coming out of U.S. labs.

Should the recent bill entitled the Patent Eligibility Restoration Act of 2023 (PERA) become law, it would override the existing jurisprudence and redefine which inventions are eligible...

The Federal Circuit upheld a decision of the district court that claims directed to poll based networking system are not patent eligible. Trinity Info Media, LLC v. Covalent, Inc., Case No. 22-1308...

Einstein's aphorism that doing the same thing over and over again and expecting a different outcome is a hallmark of madness (or at least an inability to learn from the past) inevitably...

"Hope springs eternal [in the human breast]" (Alexander Pope) and "Insanity is doing the same thing over and over and expecting different results" (the latter attributed variably to...

For more than two decades now, developers and users of software have been plagued by a flood of bad patents. Software patents that describe everyday practices like watching an ad online, publishing nutrition information, meeting people nearby, or teaching a language class continue to be issued, and...

Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday.

In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.